Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
about
Modulating the Innate Immune Response to Influenza A Virus: Potential Therapeutic Use of Anti-Inflammatory DrugsSomething old, something new and something very old: drugs for treating type 2 diabetesEffects of valproic acid and pioglitazone on cell cycle progression and proliferation of T-cell acute lymphoblastic leukemia Jurkat cellsPPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumptionNicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.Feed-forward transcriptional programming by nuclear receptors: regulatory principles and therapeutic implicationsSuppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.Cardiometabolic interventions - focus on transcriptional regulators.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.PPARγ signaling and metabolism: the good, the bad and the future.Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation.Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonistsRefocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes.The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor-γ in human lung adenocarcinoma A549 cells.PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.Distinct but complementary contributions of PPAR isotypes to energy homeostasis.Evaluation of Protein Kinase Cβ and PPARγ Activity in Diabetic Rats Supplemented with Momordica charantiaProtective role of peroxisome proliferator-activated receptor-β/δ against pulmonary oxygen toxicity mediated through changes in NOS expression levels.Recent advances in understanding/managing type 2 diabetes mellitus.HBXIP activates the PPARδ/NF-κB feedback loop resulting in cell proliferation.Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.The CD36-PPARγ Pathway in Metabolic Disorders.
P2860
Q26800158-15AC9E0A-F18C-4761-BDF5-0814DC9115B5Q26865663-6F7B1EEE-1C6C-4963-B01B-543AA8F43DADQ28831371-2339CCD6-D10B-421A-8F5C-32493E559BF7Q30241952-5693AE5F-E162-486F-9617-2C4F76BB779CQ34302561-DE452BDE-6EDC-4021-994D-E2EC6ADE4051Q34712851-880CDDEC-AC99-4378-A07F-04A56A9ACFD1Q35067776-E56AF7DB-89C3-45A2-A88E-79CE83B9A582Q35827011-D7C94E16-F31A-4C63-9860-F94E825D45DDQ36642430-A44233C7-9652-4907-AD6F-8CC5FFF33B33Q37161933-06BBC35B-C173-40F1-BDEF-02220C1B9CE7Q37254899-84214D1D-C1CC-4773-B0E1-2DEB4D1539E0Q37407887-21507962-14D9-4B64-9683-31E66E8851C6Q37662933-31AF0940-EB77-48C6-9697-0572FDA2CE7BQ37679639-0BD7B6A9-1979-4BB3-B1D8-C7233B2B3672Q38110581-BC76DEA9-D600-419F-A347-C7A3AF902485Q38160494-2FDB604A-AA9E-4F6A-B7EA-CA48608CFB10Q38201960-079CCD54-D2A1-4224-B06B-847192D2E36BQ38222135-E3BECF9A-3E70-4AF4-B598-A003D365E938Q39017939-5AE8695A-1395-4053-BC1F-BC4077C0B542Q39145017-F208EB07-F422-4727-B3F4-EDDDE2535B6CQ39214885-A53964D4-45A1-43A5-A213-98EC79E51F08Q41518524-7B7ED2CC-2DDD-439A-89A8-909AA8922449Q45239150-967BA692-26F5-4ABB-A590-94C77B34BAC8Q47161786-C82660FF-B84A-4E8C-8C86-D3A55479E28FQ49724331-B7CFD710-A7DA-4E56-BCAA-0415D74199CAQ51157373-DE7675A4-3772-4A74-BB6F-B479BA65B92DQ54945060-C74875EC-2075-4B8D-884E-F4B59BC663AC
P2860
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Modulating peroxisome prolifer ...... perience, and future prospects
@ast
Modulating peroxisome prolifer ...... perience, and future prospects
@en
Modulating peroxisome prolifer ...... perience, and future prospects
@nl
type
label
Modulating peroxisome prolifer ...... perience, and future prospects
@ast
Modulating peroxisome prolifer ...... perience, and future prospects
@en
Modulating peroxisome prolifer ...... perience, and future prospects
@nl
prefLabel
Modulating peroxisome prolifer ...... perience, and future prospects
@ast
Modulating peroxisome prolifer ...... perience, and future prospects
@en
Modulating peroxisome prolifer ...... perience, and future prospects
@nl
P2093
P2860
P1476
Modulating peroxisome prolifer ...... perience, and future prospects
@en
P2093
Jorge Plutzky
Michael Farkouh
R. Scott Wright
Robert S. Rosenson
P2860
P304
P356
10.1016/J.AHJ.2012.06.023
P407
P577
2012-11-01T00:00:00Z